iShares Biotechnology ETF
318 hedge funds and large institutions have $5.2B invested in iShares Biotechnology ETF in 2014 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 96 increasing their positions, 117 reducing their positions, and 31 closing their positions.
39% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 31
21% more funds holding in top 10
Funds holding in top 10: 14 → 17 (+3)
21% more capital invested
Capital invested by funds: $4.31B → $5.2B (+$884M)
4% more funds holding
Funds holding: 307 → 318 (+11)
18% less repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 117
22% less call options, than puts
Call options by funds: $461M | Put options by funds: $594M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$280M |
| 2 |
Goldman Sachs
New York
|
+$123M |
| 3 |
Citigroup
New York
|
+$119M |
| 4 |
Morgan Stanley
New York
|
+$29.3M |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$29.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$63.6M |
| 2 |
CM
Churchill Management
Los Angeles,
California
|
-$42.6M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$18.7M |
| 4 |
EAM
Eclectica Asset Management
London,
United Kingdom
|
-$14.9M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.6M |
IBB Hedge Fund Activity: Q3 2014 in Review
318 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2014, worth a combined $5.2B — up 21% from $4.31B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new IBB positions and 31 closed out — a net gain of 12 holders — while 96 added to existing stakes and 117 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $280M. The largest seller was Mirae Asset Global Investments, cutting an estimated $63.6M.
- 318 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2014, up from 307 in Q2 2014.
- Funds reported $5.2B of iShares Biotechnology ETF stock for Q3 2014, up 21% quarter-over-quarter.
- 43 funds opened new iShares Biotechnology ETF positions in Q3 2014 and 31 closed out, a net change of +12 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2014 was JP Morgan Chase, an estimated $280M added.
- The largest iShares Biotechnology ETF seller in Q3 2014 was Mirae Asset Global Investments, an estimated $63.6M sold.
Based on aggregated 13F filings for Q3 2014.